Enovis (ENOV) Current Deferred Revenue (2010 - 2011)
Enovis' (ENOV) quarterly Current Deferred Revenue came in at $14.7 million in Q4 2011, down 14.76% year-over-year from $17.2 million in Q4 2010, and up 8.25% quarter-over-quarter from $13.6 million in Q3 2011.
Powered by 
Analysis
Enovis (ENOV) Current Deferred Revenue (2010 - 2011) Analysis & Trends
Enovis (ENOV) has reported Current Deferred Revenue for 2 consecutive years, with $14.7 million the latest figure, recorded in Q4 2011.
- On a quarterly basis, Current Deferred Revenue fell 14.76% year-over-year to $14.7 million in Q4 2011; TTM through Dec 2011 was $14.7 million, a 14.76% decrease from a year earlier, with the FY2011 full-year figure at $14.7 million, down 14.76% from the prior year.
- Current Deferred Revenue was $14.7 million for Q4 2011 at Enovis, up from $13.6 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $22.2 million in Q3 2011 and troughed at $13.6 million in Q3 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.70 Bn | 177.10 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 126.56 Bn | 121.34 Bn | 1.96 Bn |
| 3 | Medtronic | 118.15 Bn | 109.33 Bn | 6.34 Bn |
| 4 | Stryker | 104.94 Bn | 101.46 Bn | 4.50 Bn |
| 5 | Boston Scientific | 64.79 Bn | 64.25 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.87 Bn | 45.62 Bn | 1.35 Bn |
| 7 | Alcon | 33.04 Bn | 31.59 Bn | 1.68 Bn |
| 8 | Dexcom | 32.07 Bn | 30.13 Bn | 830.00 Mn |
| 9 | Steris | 20.78 Bn | 20.29 Bn | 684.20 Mn |
| 10 | Enovis | 1.08 Bn | 1.07 Bn | 359.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2011 | 14.70 Mn |
| Sep 30, 2011 | 13.58 Mn |
| Jul 1, 2011 | 22.19 Mn |
| Dec 31, 2010 | 17.25 Mn |